Login
$ABBV
$294.55 +$0.00 (0.0%) After hours

$ABBV 8-K/A SEC Filings

Filed On Filing
08 May 2024 8-K/A: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 May 2020 8-K/A: Completion of Acquisition or Disposition of Assets

The following unaudited pro forma condensed combined financial information gives effect to the acquisition of Allergan plc ("Allergan") by Venice Subsidiary LLC ("Acquirer Sub"), a direct wholly-owned subsidiary of AbbVie Inc. ("AbbVie")...

06 May 2016 8-K/A: Entry into a Material Definitive Agreement

treatment request. This text has been seperately filed with the SEC.

07 Aug 2015 8-K/A: Financial Statements and Exhibits

The following unaudited pro forma condensed combined statement of earnings for the six months ended June 30, 2015 has been prepared to illustrate the estimated effects of: (i) the acquisition of Pharmacyclics, Inc. (Pharmacyclics) by Abb...

19 Mar 2013 8-K/A: Changes in Registrant's Certifying Accountant

Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support